Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2014 1
2016 1
2017 2
2018 1
2019 2
2020 1
2021 4
2022 3
2023 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort.
Lefèvre G, Bleuse S, Puyade M, Moulis G, Néel A, Abisror N, Baudet A, Bonnotte B, Dion J, Dossier A, Grall M, Lifermann F, Limal N, Lioger B, Machelart I, Mohr C, Outh R, Queyrel-Moranne V, Slama B, Tréfond L, Abou Chahla W, Ackerman F, Belfeki N, Berezne A, Blade JS, Bouderbala MA, Chebrek S, Cottin V, De Almeida S, De Masson A, Dezoteux F, Goulenok T, Jachiet V, Jouvray M, Latu I, Ledoult E, Leurs A, Lugosi M, Martin M, Melboucy-Belkhir S, Morati-Hafsaoui C, Quemeneur T, Rohmer J, Roy-Peaud F, Sanges S, Schleinitz N, Staumont-Salle D, Taillé C, Terriou L, Tieulie N, Koenga JDE, Schwarb L, Panel K, Kahn JE, Groh M; COHESion study group. Lefèvre G, et al. Allergy. 2025 Apr;80(4):1100-1110. doi: 10.1111/all.16463. Epub 2025 Jan 5. Allergy. 2025. PMID: 39757773
Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome.
Stammler R, Vallée A, Rohmer J, Grardel N, Abisror N, Chahla WA, Ackermann F, Baudet A, Belfeki N, Ben Abdelali R, Bidet A, Bladé JS, Bleuse S, Bonnotte B, Bouderbala MA, Cayuela JM, Chebrek S, Dion J, Dossier A, Duployez N, Faguer S, Flandrin-Gresta P, Galicier L, Godon C, Grall M, Jachiet V, Jouvray M, Latu I, Ledoult E, Lengline E, Leurs A, Lhermitte L, Lifermann F, Limal N, Lioger B, Lugosi M, Machelart I, Martin M, Martis N, Mauvieux L, Melboucy-Belkhir S, Mohr C, Moulis G, Mozicconacci MJ, Naguib D, Néel A, Nicolini FE, Outh R, Panel K, Preudhomme C, Puyade M, Quemeneur T, Queyrel Moranne V, Rey J, Rousselot P, Schleinitz N, Slama B, Staumont-Salle D, Taillé C, Terriou L, Tréfond L, Viallard JF, Kahn JE, Lefèvre G, Groh M; COHESion, CEREO and GBMHM groups. Stammler R, et al. J Allergy Clin Immunol Pract. 2025 Nov;13(11):3066-3076.e2. doi: 10.1016/j.jaip.2025.09.009. Epub 2025 Sep 22. J Allergy Clin Immunol Pract. 2025. PMID: 40992688
Building a Robust Investigator-Initiated Platform: The I-CARE Experience.
Kirchgesner J, Beaugerie L, Baumann C, Baert F, Rahier JF, Bergemalm D, Cañete F, Caron B, Cossignani M, Dias S, Farkas K, Girod P, Goren I, Holvoet T, Krasz S, Kumar A, Rimmer P, Sheridan J, Thut J, Uzzan M, Viazis N, Weimers P, Zagórowicz E, Buisson A, Avedano L, Rousseau H, Peyrin-Biroulet L, Sebastian S; I‐CARE Collaborator Group. Kirchgesner J, et al. Clin Pharmacol Ther. 2026 Jun;119(6):1537-1546. doi: 10.1002/cpt.70231. Epub 2026 Feb 15. Clin Pharmacol Ther. 2026. PMID: 41693257 Free PMC article.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
18 results